Diasome
PrivateLast Round
Series C
Dec 7, 2023
Est. Valuation
$86M
Total Funding Raised
$43.7M
Company Overview
Diasome is a biotechnology company that develops innovative, cell-targeted therapies aimed at treating diabetes, obesity, and other metabolic disorders through proprietary liver-targeted insulins that help manage blood sugar levels effectively.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Diasome Comps
Public and private peers based on sector, stage, and business model.
Diasome Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Dec 7, 2023 | ||||
| Series B Extension | Aug 26, 2022 | ||||
| Series B | Dec 23, 2020 | ||||
| Series A | Jul 5, 2017 | ||||
| Series B | Apr 15, 2008 |
Diasome Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Quaker Partners Management | Series B |
| Devon Park BioVentures | Series B |
| Black Beret Life Sciences | Series A |
| JDRF | Series A |
| T1D Fund | Series A |
| Medicxi | Series A |
| McDonald Partners | Series A |
Diasome Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Diasome's valuation, stock price, and market status.
